Telaprevir for retreatment of HCV infection.

By S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, R. Focaccia, Z. Younossi, G. Foster, A. Horban and 15 more. New England Journal of Medicine, 2011

1,641 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/e69bb3e395a942aa2453f5e7c43179bb7b4a73de

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Christoph Sarrazin
2. A. Aghemo
3. G. Dusheiko
4. L. Seeff
5. M. Puoti
6. X. Forns
7. J. Pawlotsky

In Hepatology

1. Christoph Sarrazin
2. A. Aghemo
3. Andrew K. Burroughs
4. G. Dusheiko
5. L. Seeff
6. M. Puoti
7. X. Forns
8. J. Pawlotsky

Citations in the corpus

• EASL Recommendations on Treatment of Hepatitis C 2015. (2015, background): “In the Phase III trials of boceprevir and telaprevir in HCV genotype 1 treatment-naïve patients, triple therapy regimens achieved higher SVR rates than PegIFN-a and ribavirin dual therapy, of the order of 65% to 75% [7] [8] [9] [10].”
• EASL Recommendations on Treatment of Hepatitis C 2018. (2018, background): “In the phase III trials of boceprevir and telaprevir in HCV genotype 1 treatment-naïve patients, triple therapy regimens achieved higher SVR rates than pegylated IFN-α/ribavirin dual therapy, of the order of 65% to 75% [4-7].”
• An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (2011, methodology): “Two inhibitors of the NS3/4A serine protease, boceprevir (BOC) and telaprevir (TVR), have demonstrated potent inhibition of HCV genotype 1 replication and markedly improved SVR rates in treatment-naive and treatment-experienced patients.(12,13,16,17) Limited phase 2 testing has shown that TVR also h”
• EASL Clinical Practice Guidelines: Liver transplantation. (2016, background): “Unfortunately, response rates are low in cirrhotic patients, particularly in those who are previous null responders (a common situation in patients awaiting LT) [33].”
• EASL Recommendations on Treatment of Hepatitis C 2016. (2017, background): “In the phase III trials of boceprevir and telaprevir in HCV genotype 1 treatment-naïve patients, triple therapy regimens achieved higher SVR rates than pegylated IFN-α/ribavirin dual therapy, of the order of 65% to 75% [4-7].”